This article has been cited by other articles in PMC.
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (370K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
These references are in PubMed. This may not be the complete list of references from this article.
Creighton AM, Hellmann K, Whitecross S. Antitumour activity in a series of bisdiketopiperazines. Nature. 1969 Apr 26;222(5191):384–385.[PubMed]
Hellmann K, Burrage K. Control of malignant metastases by ICRF l59. Nature. 1969 Oct 18;224(5216):273–275.[PubMed]
Hellmann K, Field EO. Effect of ICRF159 on the mammalian cell cycle: significance for its use in cancer chemotherapy. J Natl Cancer Inst. 1970 Mar;44(3):539–543.[PubMed]
Hellmann K, Newton KA, Whitmore DN, Hanham IW, Bond JV. Preliminary clinical assessment of I.C.R.F. 159 in acute leukaemia and lymphosarcoma. Br Med J. 1969 Mar 29;1(5647):822–824.[PMC free article][PubMed]
Lewis MG, Ikonopisov RL, Nairn RC, Phillips TM, Fairley GH, Bodenham DC, Alexander P. Tumour-specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Br Med J. 1969 Sep 6;3(5670):547–552.[PMC free article][PubMed]
Salsbury AJ, Burrage K, Hellmann K. Inhibition of metastatic spread by I.C.R.F. 159: selective deletion of a malignant characteristic. Br Med J. 1970 Nov 7;4(5731):344–346.[PMC free article][PubMed]
Sharpe HB, Field EO, Hellmann K. Mode of action of the cytostatic agent "ICRF 159". Nature. 1970 May 9;226(5245):524–526.[PubMed]
Articles from Proceedings of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press